BioPharmSignal logoBioPharmSignal

Biotech News

iBio Announces $26 Million Private Placement

Ibio Inc (IBIO)Ibio IncFinancing

IBIO (IBIO) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is ibio.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

IBIOIbio Inc2026-06-02 11:00 EST

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

IBIOIbio Inc2026-04-08 11:00 EST

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

ENTXEntera Bio2026-07-27 12:30 EST

Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement

ALVOAlvotech2026-06-18 09:51 EST

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

ALVOAlvotech2026-06-16 03:59 EST

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

STTKShattuck Labs2025-08-26 10:30 EST

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

STTKShattuck Labs2025-08-05 10:30 EST

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

APGEApogee Therapeutics2026-03-26 20:01 EST

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million

APGEApogee Therapeutics2026-03-25 01:53 EST

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

CHRSCoherus BioSciences, Inc.2026-02-17 21:11 EST

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

View all latest news

Ibio Inc

AI-Enabled Antibody Discovery iBio develops antibodies using computational discovery and engineering platforms designed to improve target selection and molecular properties. IBIO-600 IBIO-600 is a long-acting anti-myostatin antibody intended to preserve lean mass and improve body composition during obesity treatment. Cardiopulmonary...

Recent company news

IBIOIbio Inc2026-08-04 11:00 EST

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

IBIOIbio Inc2026-07-01 11:00 EST

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

IBIOIbio Inc2026-06-02 20:01 EST

iBio to Participate in Upcoming Healthcare Investor Conferences

IBIOIbio Inc2026-06-02 11:00 EST

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

IBIOIbio Inc2026-05-12 20:05 EST

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

Stock data

Close
1.39 USD
Market cap
87.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States